HOME
• effexor ptsd
• switching for paxil to effexor
• weight gain on effexor
• effexor tinnitus

losing weight after effexor

All reported events are losing weight after effexor except those already listed losing weight after effexor Table 2 and those events for which a drug cause was remote. This increase was duration dependent over the study losing weight after effexor and tended to be greater with higher doses. Although these events occurred during treatment with venlafaxine, causality has not been determined. There is a single case report of breast pain associated with venlafaxine therapy. Dermatologic At least 3 cases of venlafaxine- induced alopecia have been reported. The authors state that it is possible that the anasarca was due to an allergic or losing weight after effexor type hypersensitivity reaction losing weight after effexor the circumstances. There are numerous case reports of withdrawal symptoms following abrupt discontinuation of treatment, and a single case report of severe tinnitus associated with venlafaxine. Withdrawal effects occur upon abrupt discontinuation of treatment and the severity of symptoms appears to be dependent on length of therapy and dose (including low dose therapy). Although these events occurred during treatment with venlafaxine, causality has not been determined. Respiratory Respiratory side effects have frequently included pharyngitis, sinusitis, and yawning. Respiratory side effects reported in premarketing Phase 3 trials have included increased cough, dyspnea, asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration, atelectasis, hemoptysis, hypoventilation, hypoxia, larynx edema, pleurisy, pulmonary embolus, and sleep apnea.

Go To...

• effexor irrational behavior
• effexor activist
• good things about effexor
• effexor panic disorder
• effexor worsens depression

losing weight after effexor

Dermatologic side effects reported in premarketing Phase 3 trials have included pruritus, acne, alopecia, contact dermatitis, dry skin, eczema, maculopapular rash, psoriasis, urticaria, brittle nails, erythema nodosum, exfoliative dermatitis, lichenoid dermatitis, hair discoloration, skin discoloration, furunculosis, hirsutism, leukoderma, miliaria, petechial rash, pruritic rash, pustular rash, vesiculobullous rash, seborrhea, skin atrophy, skin hypertrophy, skin striae, and decreased sweating. In addition, in premarketing assessment of Effexor XR (the extended release form of venlafaxine), multiple doses losing weight after effexor administered to 705 patients in Phase 3 major depressive disorder studies and Effexor was administered to 96 patients. The authors state that it is possible that the anasarca was due to an allergic or delayed- type hypersensitivity reaction given the circumstances. There are numerous case reports of withdrawal symptoms following abrupt discontinuation of treatment, and a single case report of losing weight after effexor tinnitus associated with venlafaxine. Withdrawal effects occur upon abrupt discontinuation of treatment and losing weight after effexor severity of symptoms appears to be dependent on length of therapy and dose (including low dose therapy). The conditions and duration of exposure to venlafaxine in both development programs varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient (Effexor only) and outpatient studies, fixed-dose and titration studies. All reported events are included except those already listed in Table losing weight after effexor and those events for which a drug cause was remote. In a flexible-dose study, with doses in the range of 200 to 375 mg/day and mean dose greater than 300 mg/day, the mean change in heart rate was 8.5 beats per minute compared with 1.7 beats per minute for placebo. Other Events losing weight after effexor During the Premarketing Evaluation of Venlafaxine During its premarketing assessment, multiple doses of Effexor were administered to 2897 patients in Phase 2 losing weight after effexor Phase 3 studies. Dyskinesia has also been reported. Venlafaxine has been reported to increase the pain tolerance threshold to electrical sural nerve stimulation and the threshold at which pain increases (pain losing weight after effexor losing weight after effexor of serotonin syndrome has been reported which is losing weight after effexor to have been precipitated by the combination of venlafaxine and trazodone. One small study has suggested that venlafaxine may improve attention, concentration, memory, and reaction time performance after single oral doses. Nervous system side effects losing weight after effexor in losing weight after effexor Phase 3 trials have included amnesia, confusion, depersonalization, hypesthesia, abnormal thinking, trismus, vertigo, akathisia, apathy, ataxia, circumoral paresthesia, central nervous system (CNS) stimulation, hostility, hyperesthesia, hyperkinesia, hypotonia, incoordination, myoclonus, neuralgia, neuropathy, seizure, abnormal speech, stupor, adjustment disorder, akinesia, alcohol abuse, aphasia, bradykinesia, buccoglossal syndrome, cerebrovascular accident, feeling drunk, loss of consciousness, dementia, dystonia, increased energy, facial paralysis, abnormal gait, Guillain-Barre Syndrome, hyperchlorhydria, hypokinesia, hysteria, impulse control difficulties, increased libido, motion sickness, neuritis, nystagmus, paresis, decreased or increased reflexes, and torticollis. However, there is a dose dependency for blood pressure increase. Laboratory Changes Of the serum chemistry and hematology parameters monitored during clinical trials with Effexor, a statistically significant difference with placebo was seen only for serum cholesterol. Clinically relevant increases in serum cholesterol, defined as 1) a final on-therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL or 2) an average on‑therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients. ECG Changes In an analysis of ECGs obtained in 769 patients treated with Effexor and 450 patients treated with placebo in controlled clinical trials, the only statistically significant difference observed was for heart rate, ie, a mean increase from baseline of 4 beats per minute for Effexor. Risk factors for the development of SSRI- associated hyponatremia including advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum sodium levels have been identified. The onset of venlafaxine- associated interstitial pneumonitis has ranged from 1 to 18 months after initial exposure to losing weight after effexor drug and symptomatic improvement occurred after discontinuation losing weight after effexor venlafaxine and treatment with corticosteroids. Top More Effexor resources Effexor Detailed Consumer Information (PDR) Effexor Prescribing Information (FDA) Effexor Consumer losing weight after effexor Advanced Consumer (Micromedex) - Includes Dosage Information Effexor MedFacts Consumer Leaflet (Wolters Kluwer) Venlafaxine Prescribing Information (FDA) Effexor XR Prescribing Information (FDA) Effexor XR Extended-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer). These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. Although these events occurred during treatment with venlafaxine, causality has not been determined. Impaired coordination and balance have been reported in postmarketing studies. Seizures have been reported in 0.26% of treated patients during premarketing testing. The onset of venlafaxine- associated interstitial pneumonitis has ranged from 1 to 18 losing weight after effexor after initial exposure to the drug losing weight after effexor symptomatic improvement occurred after discontinuation of venlafaxine and treatment with corticosteroids. Top More Effexor resources Effexor Detailed Consumer Information (PDR) Effexor Prescribing Information (FDA) Effexor Consumer Overview Effexor Advanced Consumer (Micromedex) losing weight after effexor Includes Dosage Information Effexor MedFacts Consumer Leaflet (Wolters Kluwer) Venlafaxine Prescribing Information (FDA) Effexor XR Prescribing Information (FDA) Effexor XR Extended-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer). In all losing weight after effexor hair re- growth occurred within 2 to 4 weeks following discontinuation of venlafaxine. Dermatologic side effects have included sweating in up to approximately 14% of treated patients. Angle-closure glaucoma has been reported rarely. Ocular side effects reported in premarketing Phase 3 trials have included abnormality of accommodation, mydriasis, conjunctivitis, diplopia, dry eyes, eye pain, photophobia, visual field defect, blepharitis, cataract, chromatopsia, conjunctival edema, corneal lesion, exophthalmos, eye hemorrhage, glaucoma, retinal hemorrhage, subconjunctival losing weight after effexor keratitis, miosis, papilledema, decreased pupillary reflex, scleritis, and uveitis. Experience with the immediate-release venlafaxine showed that sustained hypertension was dose-related, increasing from 3% to 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. The rule for including events was to enumerate those that occurred at an incidence of 5% losing weight after effexor more for at least one of the venlafaxine groups and for which the incidence was at least twice the placebo incidence for at least one Effexor group. This increase was duration dependent over the study period and losing weight after effexor to be greater with higher doses.